FI118514B - A-ryhmän streptokokin polysakkaridi, immunogeeniset koostumukset ja menetelmät - Google Patents

A-ryhmän streptokokin polysakkaridi, immunogeeniset koostumukset ja menetelmät Download PDF

Info

Publication number
FI118514B
FI118514B FI964189A FI964189A FI118514B FI 118514 B FI118514 B FI 118514B FI 964189 A FI964189 A FI 964189A FI 964189 A FI964189 A FI 964189A FI 118514 B FI118514 B FI 118514B
Authority
FI
Finland
Prior art keywords
group
polysaccharide
protein
conjugate
immunogenic
Prior art date
Application number
FI964189A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI964189A0 (fi
FI964189A (fi
Inventor
Joseph Y Tai
Milan S Blake
John B Zabriskie
Francis Michon
Original Assignee
Baxter Healthcare Sa
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa, Univ Rockefeller filed Critical Baxter Healthcare Sa
Publication of FI964189A0 publication Critical patent/FI964189A0/fi
Publication of FI964189A publication Critical patent/FI964189A/fi
Application granted granted Critical
Publication of FI118514B publication Critical patent/FI118514B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
FI964189A 1994-04-21 1996-10-18 A-ryhmän streptokokin polysakkaridi, immunogeeniset koostumukset ja menetelmät FI118514B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23122994 1994-04-21
US08/231,229 US5866135A (en) 1994-04-21 1994-04-21 Group A streptococcal polysaccharide immunogenic compositions and methods
PCT/US1995/004973 WO1995028960A1 (fr) 1994-04-21 1995-04-20 Compositions de polysaccharides de streptocoques du groupe a ayant des proprietes immunogenes et procedes associes
US9504973 1995-04-20

Publications (3)

Publication Number Publication Date
FI964189A0 FI964189A0 (fi) 1996-10-18
FI964189A FI964189A (fi) 1996-12-18
FI118514B true FI118514B (fi) 2007-12-14

Family

ID=22868303

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964189A FI118514B (fi) 1994-04-21 1996-10-18 A-ryhmän streptokokin polysakkaridi, immunogeeniset koostumukset ja menetelmät

Country Status (17)

Country Link
US (2) US5866135A (fr)
EP (1) EP0754055B1 (fr)
JP (1) JPH09512276A (fr)
CN (1) CN1159064C (fr)
AT (1) ATE196605T1 (fr)
AU (1) AU709797B2 (fr)
BR (1) BR9507400A (fr)
CA (1) CA2188284C (fr)
DE (1) DE69518978T2 (fr)
DK (1) DK0754055T3 (fr)
ES (1) ES2151597T3 (fr)
FI (1) FI118514B (fr)
GR (1) GR3034916T3 (fr)
NO (1) NO321321B1 (fr)
PL (1) PL181037B1 (fr)
PT (1) PT754055E (fr)
WO (1) WO1995028960A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
EP1087791B1 (fr) * 1998-04-15 2005-09-21 Mayo Foundation for Medical Education and Research Inhibition d'anticorps xenoreactifs
EP1880735A3 (fr) * 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccin
US7256265B2 (en) 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
IL153558A0 (en) * 2000-06-20 2003-07-06 Shire Biochem Inc Streptococcus antigens
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
US20020192205A1 (en) * 2001-05-11 2002-12-19 Francis Michon Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci
WO2003015815A1 (fr) * 2001-08-21 2003-02-27 The Brigham And Women's Hospital, Inc. Vaccins conjugues ameliores
AU2003252017A1 (en) * 2002-07-19 2004-02-09 The Regents Of The University Of California Methods and compositions for modulating agonist-induced downregulation of g protein-coupled receptors
US20040197845A1 (en) * 2002-08-30 2004-10-07 Arjang Hassibi Methods and apparatus for pathogen detection, identification and/or quantification
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20100189740A1 (en) * 2007-06-20 2010-07-29 Francis Michon Modified polysaccharides for conjugate vaccines
EP2045201A1 (fr) * 2007-10-02 2009-04-08 M T C - Macchine Trasformazione Carta S.r.l. Procédé de rembobinage et machine de rembobinage l'exécutant
ES2566740T3 (es) * 2008-09-17 2016-04-15 Glaxosmithkline Biologicals Sa Vacunas y agentes terapéuticos de GAS en combinación
CA2777837C (fr) 2008-10-27 2017-07-11 Novartis Ag Procede de purification
JP5344558B2 (ja) 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
AR074273A1 (es) 2008-11-05 2011-01-05 Wyeth Corp Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo
US20130149331A1 (en) * 2011-05-03 2013-06-13 Peng George Wang Rhamnose and forssman conjugated immunogenic agents
US20140294930A1 (en) 2011-08-04 2014-10-02 The Regents Of The University Of California STREPTOCOCCAL GlcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
AU2018328037B2 (en) 2017-09-07 2024-03-07 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
EP3740211A4 (fr) * 2018-01-18 2021-04-14 Endoprotech, Inc Traitement d'un dysfonctionnement microvasculaire

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods

Also Published As

Publication number Publication date
FI964189A0 (fi) 1996-10-18
NO964413D0 (no) 1996-10-17
US5866135A (en) 1999-02-02
AU2296795A (en) 1995-11-16
PL181037B1 (pl) 2001-05-31
PT754055E (pt) 2001-02-28
US7332173B2 (en) 2008-02-19
CA2188284A1 (fr) 1995-11-02
EP0754055A1 (fr) 1997-01-22
AU709797B2 (en) 1999-09-09
FI964189A (fi) 1996-12-18
ES2151597T3 (es) 2001-01-01
CA2188284C (fr) 2001-04-17
WO1995028960A1 (fr) 1995-11-02
JPH09512276A (ja) 1997-12-09
PL316906A1 (en) 1997-02-17
EP0754055B1 (fr) 2000-09-27
NO964413L (no) 1996-12-17
DK0754055T3 (da) 2000-12-18
CN1149835A (zh) 1997-05-14
NO321321B1 (no) 2006-04-24
BR9507400A (pt) 1997-10-07
US20050163808A1 (en) 2005-07-28
DE69518978T2 (de) 2001-03-15
ATE196605T1 (de) 2000-10-15
GR3034916T3 (en) 2001-02-28
DE69518978D1 (de) 2000-11-02
CN1159064C (zh) 2004-07-28

Similar Documents

Publication Publication Date Title
FI118514B (fi) A-ryhmän streptokokin polysakkaridi, immunogeeniset koostumukset ja menetelmät
Paoletti et al. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine
JP4308174B2 (ja) グループｂストレプトコッカス・タイプｉｉおよびタイプｖ多糖−蛋白質接合ワクチン
Wessels et al. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
EP0598818B1 (fr) Vaccin a base de conjugues de polysaccharide-o d'escherichia coli et d'une proteine
Wessels et al. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine
Dale et al. Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein.
Wessels et al. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine
US5843461A (en) Group B streptococcus type II polysaccharide-tetanus toxoid conjugate vaccines
Daniels et al. Characterization of the Salmonella paratyphi C Vi polysaccharide
Devi et al. Capsular polysaccharide-protein conjugate vaccines of carbotype 1 Vibrio vulnificus: construction, immunogenicity, and protective efficacy in a murine model
EP2566508A2 (fr) Conjugaison de polysaccharide à une entérotoxine thermolabile (lt) d'e.coli détoxifiée, utilisée comme vaccin
Vincent-Ballereau et al. Haemophilus type B conjugate vaccine: postimmunization kinetics of IgM and IgG antibody responses in ten vaccinated children

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118514

Country of ref document: FI